Login
$ODTX
$19.39 +$0.25 (1.31%) Live

$ODTX 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis

20 Oct 2026 8-K: Regulation FD Disclosure

Forward-looking statements and third-party information This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other...

09 Sep 2026 8-K: Regulation FD Disclosure

Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, In...

04 Aug 2026 8-K: Results of Operations and Financial Condition

Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October

23 Jun 2026 8-K: Regulation FD Disclosure

Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, In...

17 Jun 2026 8-K: Results of Operations and Financial Condition

Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis

11 May 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SHARE PURCHASE AGREEMENT (this “Agreement”) is entered into as of May 7, 2026 (the “Effective Date”), by and between TPG LSI Rise Orazio II, L.P. is a Delaware limited partnership (the “Investor”), and Odyssey Therapeutics, Inc., a ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support